{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:26:46Z","timestamp":1790468806803,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3472,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1093\/annonc\/mdp460","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T01:57:09Z","timestamp":1256867829000},"page":"1196-1202","source":"Crossref","is-referenced-by-count":39,"title":["Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study"],"prefix":"10.1016","volume":"21","author":[{"given":"J.W.","family":"Sweetenham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.R.","family":"Tubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.W.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.I.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Rimsza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Braziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.D.","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp460_bb0010","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0015","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0020","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0025","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0030","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp460_bb0035","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp460_bb0040","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas MD Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp460_bb0045","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mdp460_bb0050","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0055","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOX-P3 regulatory T-cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0060","first-page":"224A","article-title":"The architectural pattern of FOXP3+ T-cells is an independent predictor of survival in patients with follicular lymphoma","volume":"19","author":"Farinha","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdp460_bb0065","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp460_bb0070","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","article-title":"Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients","volume":"24","author":"Alvaro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp460_bb0075","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","article-title":"A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone","volume":"13","author":"Taskinen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp460_bb0080","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","article-title":"High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial","volume":"26","author":"Canioni","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp460_bb0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.13574","article-title":"Impact of tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols","volume":"94","author":"de Jong","year":"2009","journal-title":"Hematologica"},{"key":"10.1093\/annonc\/mdp460_bb0090","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1080\/10428190701665954","article-title":"Biologic predictors in follicular lymphoma: importance of markers of immune response","volume":"48","author":"Kelley","year":"2007","journal-title":"Leuk Lymph"},{"key":"10.1093\/annonc\/mdp460_bb0095","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1182\/blood-2005-10-4222","article-title":"Prognostic significance of bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study","volume":"107","author":"Winter","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0100","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0105","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2000.18.10.2010","article-title":"Interferon alfa consolidation after intensive chemotherapy does not prolong the progression free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group phase III study 8809","volume":"18","author":"Fisher","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp460_bb0110","first-page":"843a","article-title":"A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800","volume":"98","author":"Maloney","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0115","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","article-title":"A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911","volume":"102","author":"Press","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0120","series-title":"World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"10.1093\/annonc\/mdp460_bb0125","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mdp460_bb0130","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdi269","article-title":"Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems","volume":"16","author":"Perea","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp460_bb0135","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood.V95.6.2084","article-title":"A monoclonal antibody (MUM1p) detects expression of the MUM1\/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells","volume":"95","author":"Falini","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0140","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/modpathol.3880373","article-title":"Analysis of MUM1\/IRF4 protein expression using tissue microarrays and immunohistochemistry","volume":"14","author":"Natkunam","year":"2001","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdp460_bb0145","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2006-09-045989","article-title":"CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features","volume":"109","author":"Karube","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp460_bb0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3324\/haematol.10682","article-title":"MUM1 expression dichotomizes follicular lymphoma into predominantly, MUM1-negative low grade and MUM-positive high-grade subtypes","volume":"92","author":"Naresh","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdp460_bb0155","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ccr.2007.08.011","article-title":"A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma","volume":"12","author":"Saito","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdp460_bb0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ccr.2007.08.012","article-title":"The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF downregulates BCL6 expression","volume":"12","author":"Lossos","year":"2007","journal-title":"Cancer Cell"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419392841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419392841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/6\/1196\/445570\/mdp460.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:30:38Z","timestamp":1624699838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419392841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0923753419392841"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp460","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}